Glucagon clinical trials
Also written LY900018, GlucaGen, AMG504-1 and Baqsimi.
Includes 1 study of Glucagon hydrochloride.
How each study uses Glucagon is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Glucagon studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Nov 1960 · GLUCAGON · NDA 012122 (FDA, Drugs@FDA; as glucagon hydrochloride)
- European Union
- 16 Dec 2019 · Baqsimi · EMEA/H/C/003848 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
79 studies that test it; most in 2017 (9); 1 more planned to start later
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 8 |
| 2014 | 6 |
| 2015 | 8 |
| 2016 | 6 |
| 2017 | 9 |
| 2018 | 8 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 31 · Other 50
Eli Lilly and Company (13) · Xeris Pharmaceuticals (11) · Steno Diabetes Center Copenhagen (6) · Institut de Recherches Cliniques de Montreal (4) · Joslin Diabetes Center (3) · University Health Network, Toronto (3) · Legacy Health System (3) · AdventHealth Translational Research Institute (2)
Often tested with
Tested in the same studies.
Glucose (4) · Somatostatin (2) · Insulin, Regular, Human (2) · Octreotide (2) · Human Growth Hormone (2) · Insulin (2) · Exenatide (1) · Dasiglucagon (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test Glucagon.
- Jan 2027Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)Phase 4 · Joslin Diabetes Center
- May 2027The Postprandial Hypo-Avoid StudyPhase 4 · Steno Diabetes Center Copenhagen
- Oct 2027Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PETNot applicable · Rigshospitalet, Denmark
- Nov 2027The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.Not applicable · Bispebjerg Hospital
Studies
Open first, then newest update. How each study uses Glucagon is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 81
- Post-Prandial Carbohydrate Metabolism in Individuals With and Without Post-Bariatric Surgery Hypoglycemia (PBH)RecruitingPhase 4Joslin Diabetes CenterNCT07818707Written as Glucagon for Injection (Fresenius Kabi USA)How we know
- The Postprandial Hypo-Avoid StudyRecruitingPhase 4Steno Diabetes Center CopenhagenNCT07427251Written as Low-Dose GlucagonHow we know
- Studies of Insulin and Glucagon Action in the LiverNot yet recruitingPhase 1/2Duke UniversityNCT07300982Written as GlucagonHow we know
- Human Models of Selective Insulin Resistance: Pancreatic ClampNot yet recruitingPhase 1Columbia UniversityNCT06558422Written as GlucagonHow we know
- The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.Not yet recruitingNot applicableBispebjerg HospitalNCT06872060Written as GlucagonHow we know
- The Effects of Glucagon on Hepatic MetabolismCompletedPhase 1/2Adrian VellaNCT05500586Written as Glucagon response studyHow we know
- To Determine Tolerability to Glucagon Infusion in Obese SubjectsActive, not recruitingPhase 1AdventHealth Translational Research InstituteNCT02817659Written as GlucagonHow we know
- Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese SubjectsActive, not recruitingPhase 1AdventHealth Translational Research InstituteNCT03139305Written as GlucagonHow we know
- Glucagon Dose-Response in Patients With Post-Bariatric HypoglycemiaActive, not recruitingPhase 4Joslin Diabetes CenterNCT06986603Written as Glucagon for Injection (Fresenius Kabi USA)How we know
- Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PETActive, not recruitingNot applicableRigshospitalet, DenmarkNCT07366710Written as GlucagonHow we know
- Pancreatic Clamp in NAFLDCompletedPhase 1Columbia UniversityNCT05724134Written as GlucagonHow we know
- Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 DiabetesCompletedNot applicableSteno Diabetes Center CopenhagenNCT05379686Written as GlucaGenHow we know
- Glucagon Use in ColonoscopiesCompletedPhase 4University of California, San FranciscoNCT02078726Written as GlucagonHow we know
- Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1TerminatedPhase 2St. Olavs HospitalNCT05960565Written as GlucagonHow we know
- The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTACompletedPhase 1Yale UniversityNCT03965130Written as GlucagonHow we know
- Effect of Physiologic Hyperglucogonemia on Adipocyte MetabolismCompletedEarly Phase 1The University of Texas Health Science Center at San AntonioNCT04300049Written as Glucagon InfusionHow we know
- A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT04992312Written as Glucagon Nasal Powder [Baqsimi]How we know
- Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male VolunteersCompletedNot applicableCambridge University Hospitals NHS Foundation TrustNCT03835013Written as Glucagon (25ng/kg/min)How we know
- Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 DiabetesCompletedNot applicableSteno Diabetes Center CopenhagenNCT05076292Written as GlucaGenHow we know
- The Role of the Kidneys and Liver in the Elimination of GlucagonCompletedNot applicableUniversity Hospital, Gentofte, CopenhagenNCT05056584Written as Glucagon infusionHow we know
See all 81 studies that test Glucagon →
Given beside what is tested · 14 — Glucagon is usual care or a partner of the new treatment
- Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese AdolescentsCompletedPhase 3Novo Nordisk A/SNCT06588504Written as GlucagonHow we know
- Liver Glycogen and Hypoglycemia in HumansActive, not recruitingPhase 1Jason WinnickNCT03241706Written as GlucagonHow we know
- Dexamethasone/Pancreatic Clamp P&FWithdrawnPhase 1Columbia UniversityNCT06126354Written as GlucagonHow we know
- Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 DiabetesStatus unknownNot applicableNordsjaellands HospitalNCT05095259Written as GlucagonHow we know
- A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes MellitusCompletedPhase 1SanofiNCT02910518Written as GlucagonHow we know
- Feasibility Trial Testing the Bionic Pancreas With ZP4207CompletedPhase 2Zealand PharmaNCT02971228Written as GlucagonHow we know
- Study of LY2409021 in Participants With Type 1 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT01640834Written as GlucagonHow we know
- Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of GlucagonCompletedPhase 4Massachusetts General HospitalNCT02516150Written as GlucagonHow we know
- Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2CompletedPhase 2Institut de Recherches Cliniques de MontrealNCT02798250Written as GlucagonHow we know
- The Role of Amylin and Glucagon in T1DMCompletedPhase 3Baylor College of MedicineNCT00206258Written as Pramlintide and glucagonHow we know
- Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop OperationCompletedPhase 2Institut de Recherches Cliniques de MontrealNCT02626936Written as GlucagonHow we know
- A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT02012166Written as GlucagonHow we know
- Effect of LY2189265 on Insulin Secretion in Response to Intravenous GlucoseCompletedPhase 1Eli Lilly and CompanyNCT01300260Written as GlucagonHow we know
- To Evaluate the Response to Glucagon During HypoglycemiaCompletedPhase 1AstraZenecaNCT00817271Written as GlucagonHow we know
As the comparator · 11 — what is tested is compared with Glucagon
- A Stable Glucagon Analog Administered by a Bihormonal Closed Loop SystemWithdrawnPhase 2Inreda Diabetic B.V.NCT05454709Written as GlucaGenHow we know
- Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM ChildrenCompletedPhase 3Zealand PharmaNCT03667053Written as GlucaGen HypoKitHow we know
- A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes SubjectsCompletedPhase 3Zealand PharmaNCT03378635Written as GlucaGenHow we know
- First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.CompletedPhase 1Novo Nordisk A/SNCT03444467Written as GlucagonHow we know
- A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DMCompletedPhase 1AdociaNCT03176524Written as GlucaGen® HypoKit®How we know
- ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed GlucagonCompletedPhase 2Zealand PharmaNCT02916251Written as Glucagon (Native glucagon)How we know
- Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy VolunteersCompletedPhase 1Hospira, now a wholly owned subsidiary of PfizerNCT00745186Written as GlucagenHow we know
- A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced HypoglycemiaWithdrawnPhase 1SanofiNCT02635243Written as r-glucagonHow we know
- A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus PatientsCompletedPhase 1SanofiNCT02625636Written as r-glucagonHow we know
- Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed GlucagonCompletedPhase 2Zealand PharmaNCT02660008Written as GlucaGenHow we know
- Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a ComparatorCompletedPhase 1Zealand PharmaNCT02367053Written as GlucagonHow we know
Codes
What other systems call Glucagon · ClinicalTrials.gg INT007556
- MeSH (NLM) D005934GlucagonOne source ClinicalTrials.gov
- UNII (FDA) 76LA80IG2GGLUCAGONOne source FDA
- RxNorm 4832One source FDA
- NCI Thesaurus C520Recombinant GlucagonOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005934 | Glucagon | One source ClinicalTrials.gov |
| UNII (FDA) | 76LA80IG2G | GLUCAGON | One source FDA |
| RxNorm | 4832 | — | One source FDA |
| NCI Thesaurus | C520 | Recombinant Glucagon | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.